CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response

Cancer Immunology, Immunotherapy

Volumn 53, Issue 8, 2004, Pages 697-704

  Sfondrini, Lucia ^a   Besusso, Dario ^a   Bronte, Vincenzo ^b   Macino, Beatrice ^b   Rossini, Anna ^a   Colombo, Mario Paolo ^a   Ménard, Sylvie ^a   Balsari, Andrea ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

CpG ODNs; CTL; Tumor immunity; Vaccination

Indexed keywords

GAMMA INTERFERON; OLIGODEOXYNUCLEOTIDE; TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CPG ISLAND; CYTOKINE PRODUCTION; EVALUATION; IMMUNE RESPONSE; IN VIVO CULTURE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 3242704835     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0516-x     Document Type: Article

References (38)

1. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G (1999) An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190:651
2. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY (2001) Implication of macrophages in tumor rejection induced by CpG- oligodeoxynucleotides without antigen. Clin Cancer Res 7:3540
3. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ (2001) Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167:4878
4. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453
5. Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P (2003) Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol 171:6396
6. Carpentier AF, Chen L, Maltonti F, Delattre JY (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59:5429
7. Garboczi DN, Hung DT, Wiley DC (1992) HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A 89:3429
8. Heckelsmiller K, Rail K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G (2002) Peritumoral CpG DNA elicits a coordinated response of CDS T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169:3892
9. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740
10. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531
11. 'Jackson IJ, Chambers DM, Tsukamoto K, Copeland NG, Gilbert DJ, Jenkins NA, Hearing V (1992) A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. EMBO J 11:527
12. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ (2001) NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CPG-containing oligodeoxynucleotides. J Immunol 167:5247
13. Kranzer K, Bauer M, Lipford GB, Heeg K, Wagner H, Lang R (2000) CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 99:170
14. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709
15. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546
16. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292
17. Lipford GB, Sparwasser T, Bauer M, Zimmermann S, Koch ES, Heeg K, Wagner H (1997) Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 27:3420
18. Lipford GB, Bendigs S, Heeg K, Wagner H (2000) Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology 101:46
19. Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L (1996) Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 184:647
20. Lollini P, De Giovanni D, Nicoletti G, Bontadini A, Tazzari P, Landuzzi L, Scotlandi K, Nanni P (1990) Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. Clin Exp Met 8:215
21. Mandruzzato S, Rossi E, Bernardi F, Tosello V, Macino B, Basso G, Chiarion-Sileni V, Rossi CR, Montesco C, Zanovello P (2002) Large and dissimilar repertoire of melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol 169:4017
22. Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen MD, Kornbluth RS, Raz E (1999) Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol 11:1111
23. Rodolfo M, Castelli C, Bassi C, Accornero P, Sensi M, Parmiani G (1994) Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int J Cancer 57:440
24. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
25. Sato N, Michaelides MC, Wallack MK (1983) Transplantation immunity and cross-protection of two cultured murine colon lines. J Natl Cancer Inst 70:261
26. Sfondrini L, Besusso D, Rumio C, Rodolfo M, Ménard S, Balsari A (2002) Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 16:1749
27. Sfondrini L, Besusso D, Zoia MT, Rodolfo M, Invernizzi AM, Taniguchi M, Nakayama T, Colombo MP, Ménard S, Balsari A (2002) Absence of CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol 169:151
28. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28:2045
29. Steitz J, Bruck J, Steinbrink K, Enk A, Knop J, Tuting T (2000) Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 86:89
30. Sun S, Beard C, Jaenisch R, Jones P, Sprent J (1997) Mitogenicity of DNA from different organisms for murine B cells. J Immunol 159:3119
31. Sun Y, Song M, Stevanovic S, Jankowiak C, Paschen A, Rammensee HG, Schadendorf D (2000) Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 87:399
32. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den DP, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669
33. Wagner H (1999) Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 73:329
34. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207
35. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA (1998) Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 160:890
36. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T (1992) Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 148:4072
37. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989
38. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627